Hormone-Based Weight and Diabetes Drugs: From GLP-1 to Amylin to Ghrelin Blockers

Hormone-based therapies including GLP-1 agonists, amylin analogs, and ghrelin modulators represent the next generation of drugs for obesity and diabetes, exploiting the body's own appetite and glucose regulatory systems.

Kesty, Nicole C et al.·Expert opinion on biological therapy·2008·Moderate EvidenceReview
RPEP-01364ReviewModerate Evidence2008RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Hormone-based fuel metabolism drugs span GLP-1 agonists (semaglutide class), amylin analogs (pramlintide), PYY analogs, and ghrelin modulators for integrated obesity/diabetes treatment — exploiting endogenous regulatory peptide systems for superior metabolic control.

Key Numbers

How They Did This

review study.

Why This Research Matters

Relevant for glp-1, neuropeptides, weight-loss, diabetes.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Hormone-based fuel metabolism drugs span GLP-1 agonists (semaglutide class), amylin analogs (pramlintide), PYY analogs, and ghrelin modulators for int
Evidence Grade:
moderate evidence.
Study Age:
Published in 2008.
Original Title:
Hormone-based therapies in the regulation of fuel metabolism and body weight.
Published In:
Expert opinion on biological therapy, 8(11), 1733-47 (2008)
Database ID:
RPEP-01364

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Hormone-Based Weight and Diabetes Drugs: From GLP-1 to Amylin to Ghrelin Blockers

What was found?

Hormone-based therapies including GLP-1 agonists, amylin analogs, and ghrelin modulators represent the next generation of drugs for obesity and diabetes, exploiting the body's own appetite and glucose regulatory systems.

Read More on RethinkPeptides

Cite This Study

RPEP-01364·https://rethinkpeptides.com/research/RPEP-01364

APA

Kesty, Nicole C; Roth, Jonathan D; Maggs, David. (2008). Hormone-based therapies in the regulation of fuel metabolism and body weight.. Expert opinion on biological therapy, 8(11), 1733-47. https://doi.org/10.1517/14712598.8.11.1733

MLA

Kesty, Nicole C, et al. "Hormone-based therapies in the regulation of fuel metabolism and body weight.." Expert opinion on biological therapy, 2008. https://doi.org/10.1517/14712598.8.11.1733

RethinkPeptides

RethinkPeptides Research Database. "Hormone-based therapies in the regulation of fuel metabolism..." RPEP-01364. Retrieved from https://rethinkpeptides.com/research/kesty-2008-hormonebased-therapies-in-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.